How Do You Determine the Best Treatment Strategy?
The panel discusses a patient with high-risk CSCC, exploring how disease characteristics, immune status, and multidisciplinary input inform postoperative treatment decisions and consideration of adjuvant immunotherapy.
This is Part 2 of 4:
Part 1: When Is Surgery Alone No Longer Enough?
Part 2: How Do You Determine the Best Treatment Strategy?
Part 3: How Can the Multidisciplinary Team Optimize Patient Care?
Part 4: Practical Strategies for Multidisciplinary CSCC Care
Dr Stan Tolkachjov: This is Case 2, and so how do you determine the best treatment strategy for a patient with a high-risk cutaneous SCC?
Dr Sunandana Chandra: So, this is a 75-year-old gentleman. He has a history of CLL and prior systemic therapy for that CLL. Although, when the person first came to medical oncology, they were off of all systemic therapy for their CLL. Their CLL was pretty high risk, 13q deletion. It was diagnosed over a decade previously. And for that, he had been treated with systemic therapy, including chemotherapy, rituximab, obinutuzumab, and venetoclax. So, this person has a history of being immunosuppressed and having a dysfunctional immune system.
So, surveillance imaging showed a 1.3-centimeter, right level IIA lymph node. And here you can see on the CT scan that the lymph node is enlarged, and it looks quite asymmetric. So, then the person was sent to medical oncology. If we could look at the next slide. We then planned to do a biopsy that was interventional radiology guided. Soon after the patient underwent the biopsy, there was no post-biopsy complications, thankfully, but here you see some H&E stains of the biopsy specimen. And long story short, the lymph node was actually positive for metastatic cutaneous squamous cell carcinoma. It didn't have any of the markers for any other skin cancers, but this person did have disease in their lymph nodes.
Dr Stan Tolkachjov: As I look at this as a dermatologist, you can see that the pan-CK , or CK, is positive, and that's your squamous cell marker, of course. The P40 is also positive here, but the SOX10 and MART1 for melanoma are both negative. And that helps us out, especially with some of these poorly differentiated tumors, or de-differentiated tumors. On this particular patient, one of the things that I think you brought up really well, is important to consider, is CLL, chronic lymphocytic leukemia, that we know is a high-risk factor. Although that is not a factor in Brigham and Women's criteria, we do know it's also a high-risk factor in other type of nomograms and guidelines. So, what is our next step?
Dr Kevin Emerick: I'll mention relative to CLL, how important this is, that it's easy to be like, “Oh, it's just a prominent node. It's part of their CLL. Their CLL waxes and wanes. Let's watch it.” And so, this is where it can be important for us as providers and across the spectrum of a lymph node that's maybe behaving different than some of the CLL in the past. Or a lymph node that's in the distribution of a previous worrisome squamous cell or other skin cancer should prompt, not just a scan, but an FNA. It can be really easy to say, "Oh, it's not FNA, we'll watch." But I think it's so important here to do both imaging and FNA when you have that trigger of a lymph node that's behaving different than all the others, especially in the distribution of a skin cancer.
Dr Stan Tolkachjov: That's a great point.
Dr Sunandana Chandra: Yeah, I think we need to have a high level of suspicion for our patients who are immunocompromised, no matter what is leading to their immunocompromised state. So I was very pleased that their hematologist actually referred them quickly, as soon as they palpated the lymph node.
Dr Kevin Emerick: And I feel like, Su, this is one thing that I've seen change over the years, that our transplant colleagues, our heme-onc colleagues, there was a time when some of this was really foreign, but they are on board, especially when you engage them and say, "Hey, do they really need ritux right now, or can we scale that back?" They are really open to those conversations. They want to have them. So, it's really important that we engage them.
Dr Stan Tolkachjov: That's very true, especially in the world of PD-1s nowadays being used, right? We have to consider what kind of organ has been transplanted. And, of course, if we're talking about immunosuppression, how is that taken into account? And so, at this point, the patient had a parotidectomy, neck dissection?
Dr Sunandana Chandra: Yes. So, the patient was sent to our ENT colleagues where they underwent a parotidectomy, neck dissection, and they also then met radiation oncology, who then planned a postoperative radiation course both to the right parotid bed as well as the right neck. So, I think the few things that are important in this particular person to think about is that they are immunocompromised, we have radiologic evidence of enlarged nodes, we then biopsied it to prove that the CSCC had nodal involvement, and then the patient underwent disease, and was rendered disease-free. However, although it's not stated here, the patient did have perineural invasion. And it was of a large-caliber nerve. And so, I was already in discussion with radiation oncology as to what the next steps might be after the patient finished radiation.
Dr Stan Tolkachjov: I think that's a great point. When you do see PNI, perineural invasion, especially with large nerves, to me, whether I'm doing Mohs surgery, we're doing excisional surgery, that's something that we have to write down. We may not know that until after the biopsy is done. Of course, in this patient, he had lymphatic metastases, but at the primary surgery time, and I think Dr Emerick will probably agree with me, as soon as we see a PNI, that's something we've got to think about local control with radiation as well, right? Because that's a big part of what we see is going to upstage that patient.
What do you think about this patient? We discussed that they have already had surgery at this point. Where does post-op radiation fit within this patient?
Dr Mehran Yusuf: Yeah, absolutely. I definitely echo the points you all have made. We look at patients who are high risk, and this patient, both because of their immune suppression, as well as having involved lymph node, meet a lot of our standard high-risk factors. I think we look at PNI, and it's important to separate PNI from perineural spread, because particularly with a large-caliber nerve, we always worry about people who may have had some cranial nerve palsies before surgery. I think that clinical history ends up being so, so important, because you guys know after surgery, it'll be normal to have some level of numbness in that distribution. So, I think spending time to tease that out with the patient ends up being really important.
I 100% agree with you, Stan. The caliber of the nerve can be important. We do have some data now that if you even have smaller-caliber PNI, the number of individual nerves can be a helpful thing to get an idea. We're looking for basically surrogates for how this tumor is going to behave. Is it going to come back locally? Is it going to latch along those nerves? And so, those are often things that are really helpful to get from your pathologist, from your derm path, from your Mohs surgeon. Intraoperatively, sometimes our surgeons will note they can see disease going into the facial nerve when they do the parotid dissection. Very, very important. It helps, the imaging we order. We'll often get MRI that has fat suppression sequences to try to image the nerve and the retrograde pathway. This is not super common, but we've already had a situation where maybe only 5% of cutaneous squames go to nodes. And so, we know there are cases where somebody has perineural spread. The common pattern of failures is after surgery, even after radiation, if you're not tracing that nerve back to skull base, is along that central pathway. In the past, that's been devastating. Now that we have newer therapies, we're getting some newer options, but those are all things that I try to consider in terms of deciding what to target with radiation and if somebody may need it.
Dr Stan Tolkachjov: Kevin?
Dr Kevin Emerick: I think that it's important for us to, again, be specific about our language around perineural spread and, as you mentioned, and the idea of clinical nerve spread. Which means specifically, we talk about in the head and neck region, we're talking about cranial nerves. We're talking about facial nerve and trigeminal nerve. And especially as we start thinking about, again, that C-POST criteria, that's what was in that trial, was spread along a clinical nerve, ie, facial nerve, trigeminal nerve. Some of the smaller-caliber nerves or the quote-unquote "large caliber," meaning greater than 0.1, is different than involving a facial nerve or a trigeminal nerve. And that is really important as we think about those criteria and indications in the C-POST criteria specifically. I think one thing that's important, we jump down this path of thinking about how perineural involvement might drive postoperative therapy, but without that perineural, I just wonder if we go back and think about lymph node criteria, specifically for next steps in treatment. And Su, how many lymph nodes were involved? Do you remember? Or was it just that one single node? The things that I tend to think about, number of nodes, size of nodes, and presence of extracapsular extension or extracapsular spread, were any of those present?
Dr Sunandana Chandra: So, there was actually 3 to 4 lymph nodes and no extracapsular spread. So, for us, when we were discussing the case, the tumor-associated characteristics that were the most alarming were the number of nodes involved, as well as the PNI.
Dr Kevin Emerick: So, I think that's really important. That also then feeds into potentially a C-POST criteria of having 3 nodes involved.
Dr Sunandana Chandra: One thing I wanted to mention that I think is very important, is a person like this, although they do have high-risk features, they are now essentially cured of their disease. And so, as a medical oncologist, a question I'm always asking myself is, could I be doing more harm than good by offering them a therapy, albeit for a short duration, up to a year, but still, some of these therapies, they can have some life-altering side effects that can be quite meaningful to a person. And so, again, back to the just because I can doesn't mean I should. So, I think it's very important to talk about those risks and benefits very clearly with a person and their caregivers so that they can make a truly informed decision.
Dr Stan Tolkachjov: Any other comments?
Dr Kevin Emerick: Yes. I was going to ask you, when you think about a patient like this with CLL, what's been your experience with response to immunotherapy? Does it feel like it's the same? So that's part one. And then part two, this person with 3 lymph nodes, possible, that PNI, they get radiation. They are a candidate, based on C-POST, to think about immunotherapy. So, does that influence your enthusiasm, or lack thereof, for giving it in that setting? So, a two-part question there.
Dr Sunandana Chandra: So, for your first question, Kevin, the data shows clearly that those patients should not be excluded, although they were from trials, especially if they were on active therapies. I think the first question I do ask if I have a person with CLL in front of me is: are they on any kind of immunosuppressive therapy? Is there a way to optimize that so we can immunosuppress them the least possible? Anecdotally, I think I do see some differences in how they respond, but these are small numbers in general. It's certainly hard to make a conclusion, but I think also theoretically that does make sense. These patients have dysfunctional B cells. An entire arm of their immune system is not quite functioning up to snuff, so to speak. But I certainly wouldn't exclude them from being considered for some sort of immunotherapy agent.
Dr Kevin Emerick: Yeah. I think...
Dr Sunandana Chandra: I forgot your second question.
Dr Kevin Emerick: That's okay. No. We'll just think about then if it is a little less responsive, do you have less enthusiasm to give it in the adjuvant setting where they're already disease-free and you're reducing a risk of recurrence, as opposed to treating?
Dr Sunandana Chandra: So, yeah, that's a great question. So if you're thinking about, could I be doing more harm than good in a person who already has a dysfunctional immune system? I think that discussion really needs to be had in a thoughtful way with the person. I don't want to remove an option that is available to them and could be offered to them, but I do want them to realize that the data that we have doesn't quite fit this particular case in front of us, who has a history of pretty significant immunosuppression.
So, if a person has, they have an excellent performance status, which this person did, and they want to be aggressive, I can see a scenario where they actually do want to try treatment because they might say, “You know what, I have nothing to lose. I understand the risks and adverse events that might happen. I'll be very vigilant and I'll follow recommendations as appropriate, but I don't want to look back and have regrets.” So, you have that camp of patients, certainly. You also have another group of patients who might say, “You know what, it's not worth the risk to me. I don't want to travel. I don't want to take the risk of more side effects, etc. I will just follow your plan for surveillance.” So, it really deserves a very thorough discussion with the person in front of you.
Dr Mehran Yusuf: I'll say one thing: I echo exactly what you guys are saying. These cases are complicated. And so, I think one of the themes, however you can do it, having a multidisciplinary discussion with people who have different lenses, I think is really important. Talking about people who have one lymph node, I 100% agree with you, Kevin. There are a lot of patients who, after high-quality surgery, are at such low risk that adjuvant radiation, the side effects are not going to be worth what small benefit you get. But I think that's where having the resources, we're all at centers where it's really easy to get with colleagues. And I imagine a lot of the people who are listening are in situations where it's a little bit less easy to have access. But I think if you can develop that within your community, it doesn't have to be at the same center, but if you can find stakeholders who are interested in the cutaneous space, you really want to be able to trust your colleagues. I think there are people who are hesitant to refer to radiation oncology because there are some radiation oncologists where it's like, “If you send it to me, it's going to get radiated.” And that's definitely not how it should be for a patient with one lymph node. But I think the basin, whether it's in the parotid, whether there are other risk factors, or CLL, particularly if they're really immune suppressed, makes me worry a little bit more. Like you mentioned, we all try to be patient-centered as well. A 5% benefit to most of my patients seems really, really small. But every once in a while, you'll run into somebody who's like, “Yeah I hear these side effects, I hear small benefit, but that's what I want to do,” and so just echoing the points that you guys made I think it's just so lovely to be able to chat with people who are in the same space.
Dr Stan Tolkachjov: Yeah, I want to do a couple educational points from this case also. First of all, we mentioned MRI when a nerve may be involved. That's a good thought because we do use CT a lot of times for staging, especially lymph nodes. But when there's a nerve involved, we often consider MRI as an option. Another thing about potentially whether immunotherapy, if this patient was, wanted to get immunotherapy, would CLL make a difference in their outcomes and many of their monitoring? And lastly, because as we mentioned, most of us also have academic affiliations. I'm also in the private world and there we do have to create multidisciplinary teams that are maybe in the private world as well.
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of The Dermatologist, HMP Global, or its employees and affiliates.


